Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on AD109
7 evidence topics · 4 sources
Medications disallowed and allowed in the phase 3 trials
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote